PT - JOURNAL ARTICLE AU - Jack Khouri AU - Christy Samaras AU - Jason Valent AU - Alex Mejia Garcia AU - Beth Faiman AU - Saveta Mathur AU - Kim Hamilton AU - Megan Nakashima AU - Matt Kalaycio TI - Monoclonal gammopathy of undetermined significance: A primary care guide AID - 10.3949/ccjm.86a.17133 DP - 2019 Jan 01 TA - Cleveland Clinic Journal of Medicine PG - 39--46 VI - 86 IP - 1 4099 - http://www.ccjm.org/content/86/1/39.short 4100 - http://www.ccjm.org/content/86/1/39.full SO - Cleve Clin J Med2019 Jan 01; 86 AB - Monoclonal gammopathy of undetermined significance (MGUS) is commonly diagnosed in outpatients being worked up for an array of clinical concerns. It carries a risk of progression to myeloma and other lymphoproliferative disorders that, albeit low (1% per year), warrants regular follow-up. Patients with MGUS can be risk-stratified on the basis of the amount and type of their monoclonal protein as well as whether they have an abnormal light-chain ratio. Here, we provide a guide to the diagnosis, workup, and management of MGUS.